Value proposition

Novel Biotech dual-platform: therapeutic and drug-delivery

MediSieve is a London biotech start-up developing Magnetic Haemofiltration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. A unique, lifesaving and often cost-saving solution, there are several multi-billion-dollar markets available for this product in oncology, infectious diseases, auto-immune diseases, poisoning, drug overdose and others. Magnetic Haemofiltration has already been shown to rapidly, specifically, and effectively remove IL-6 from human plasma.

The technology has completed pre-clinical validation, including animal studies, and is expected to start clinical studies in Q2 2022. MediSieve has raised £4M in equity funding and over £4M in non-dilutive grants. Seeking a further £8M at Series A to support pivotal clinical trials and regulatory approvals. EIS eligible.

The company has been featured in numerous online and print media articles, including the Sunday Telegraph, Daily Mail, and Wired Magazine, and been winner or finalist in several start-up competitions such as Pitch@Palace, MassChallenge, OBN Awards, TCT Magazine Awards and CMS Healthcare Startup of the Year. Recently, our founder George Frodsham was awarded BBSRC Innovator of the Year and MIT Innovators Under 35.

Magnetic blood filtration and Blood-borne disease treatment